Interestingly, our results take on added clinical significance when one considers that this study and other recent reports indicate that CD44 expression is especially enriched in ER-negative, PR-negative and/or Her2-negative breast cancers which have the worst clinical prognosis and outcome [28]. Here, ESR1 is linked to breast carcinoma.